Új korszak és új szempontok a transzfúziós kórokozó-átvitel kockázatában, különös tekintettel a rendszeres plazmaeredetű készítményre szoruló haemophiliás betegekre

Translated title of the contribution: A new era of transfusion-transmitted pathogens, infections. Renewed need for updating standards for clinicans along with blood banking

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Preparative and clinical transfusiology and transfusion, a majestic part of clinical medicine saved the life of hundred millions. However, bloodborne or transmitted infections became a serious issue in France in the 1980s, when many haemophiliacs were infected by HIV or hepatitis C virus by receiving plazma FactorVIII concentrates. This resulted in a quick and powerful development of screening as well as pathogen-inactivating methods, which reduced pathogen contamination and transmission to minimal levels. Times and pathogens are continously and rather quickly changing, so during the last decade many - not only egzotic - new pathogens and diseases were recognised, and some of them (e.g., Zyka virus, Ebola, hepatitis E virus, etc.) can also be transmitted by blood or blood-component transfusions, and in some instances they escape from standard screening and inactivation procedures. Hereby we try to focus and draw attention to some of these potentially pathogenic new bloodborne microbiological agents, and along with this we try to emphasize the significance of application of updated next generation screening and inactivation procedures. Interestingly a recent British trial, based on large population data, showed some evidence of a slight increase of non-Hodgkin lymphoma incidence in patients with multiple previous transfusions. Probably these facts are even more important in haemophiliacs, who receive prophylactic treatment 3 times weekly either by plasma factor concentrates derived from multiple donors or by gene synthetic factor sources. It is important that haemophiliac patient and family should receive the necessary information, and go for a fully informed consent based on the potential advantages and hazards of a particular treatment modality, the same way as in the chronic treatment of other diseases.

Original languageHungarian
Pages (from-to)1495-1500
Number of pages6
JournalOrvosi Hetilap
Volume159
Issue number37
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Blood Banks
Blood Component Transfusion
Infection
Ebolavirus
Hepatitis E virus
Synthetic Genes
Infectious Disease Transmission
Clinical Medicine
Informed Consent
Hepacivirus
Non-Hodgkin's Lymphoma
France
Therapeutics
Tissue Donors
HIV
Incidence
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{6cef4a912e8743d4b9a5f90859bd3977,
title = "{\'U}j korszak {\'e}s {\'u}j szempontok a transzf{\'u}zi{\'o}s k{\'o}rokoz{\'o}-{\'a}tvitel kock{\'a}zat{\'a}ban, k{\"u}l{\"o}n{\"o}s tekintettel a rendszeres plazmaeredetű k{\'e}sz{\'i}tm{\'e}nyre szorul{\'o} haemophili{\'a}s betegekre",
abstract = "Preparative and clinical transfusiology and transfusion, a majestic part of clinical medicine saved the life of hundred millions. However, bloodborne or transmitted infections became a serious issue in France in the 1980s, when many haemophiliacs were infected by HIV or hepatitis C virus by receiving plazma FactorVIII concentrates. This resulted in a quick and powerful development of screening as well as pathogen-inactivating methods, which reduced pathogen contamination and transmission to minimal levels. Times and pathogens are continously and rather quickly changing, so during the last decade many - not only egzotic - new pathogens and diseases were recognised, and some of them (e.g., Zyka virus, Ebola, hepatitis E virus, etc.) can also be transmitted by blood or blood-component transfusions, and in some instances they escape from standard screening and inactivation procedures. Hereby we try to focus and draw attention to some of these potentially pathogenic new bloodborne microbiological agents, and along with this we try to emphasize the significance of application of updated next generation screening and inactivation procedures. Interestingly a recent British trial, based on large population data, showed some evidence of a slight increase of non-Hodgkin lymphoma incidence in patients with multiple previous transfusions. Probably these facts are even more important in haemophiliacs, who receive prophylactic treatment 3 times weekly either by plasma factor concentrates derived from multiple donors or by gene synthetic factor sources. It is important that haemophiliac patient and family should receive the necessary information, and go for a fully informed consent based on the potential advantages and hazards of a particular treatment modality, the same way as in the chronic treatment of other diseases.",
keywords = "Inactivation, Newly recognised bloodborne pathogens, Plasm derived coagulation factor concentrates, Screening",
author = "M. Udvardy",
year = "2018",
month = "9",
day = "1",
doi = "10.1556/650.2018.31183",
language = "Hungarian",
volume = "159",
pages = "1495--1500",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "37",

}

TY - JOUR

T1 - Új korszak és új szempontok a transzfúziós kórokozó-átvitel kockázatában, különös tekintettel a rendszeres plazmaeredetű készítményre szoruló haemophiliás betegekre

AU - Udvardy, M.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Preparative and clinical transfusiology and transfusion, a majestic part of clinical medicine saved the life of hundred millions. However, bloodborne or transmitted infections became a serious issue in France in the 1980s, when many haemophiliacs were infected by HIV or hepatitis C virus by receiving plazma FactorVIII concentrates. This resulted in a quick and powerful development of screening as well as pathogen-inactivating methods, which reduced pathogen contamination and transmission to minimal levels. Times and pathogens are continously and rather quickly changing, so during the last decade many - not only egzotic - new pathogens and diseases were recognised, and some of them (e.g., Zyka virus, Ebola, hepatitis E virus, etc.) can also be transmitted by blood or blood-component transfusions, and in some instances they escape from standard screening and inactivation procedures. Hereby we try to focus and draw attention to some of these potentially pathogenic new bloodborne microbiological agents, and along with this we try to emphasize the significance of application of updated next generation screening and inactivation procedures. Interestingly a recent British trial, based on large population data, showed some evidence of a slight increase of non-Hodgkin lymphoma incidence in patients with multiple previous transfusions. Probably these facts are even more important in haemophiliacs, who receive prophylactic treatment 3 times weekly either by plasma factor concentrates derived from multiple donors or by gene synthetic factor sources. It is important that haemophiliac patient and family should receive the necessary information, and go for a fully informed consent based on the potential advantages and hazards of a particular treatment modality, the same way as in the chronic treatment of other diseases.

AB - Preparative and clinical transfusiology and transfusion, a majestic part of clinical medicine saved the life of hundred millions. However, bloodborne or transmitted infections became a serious issue in France in the 1980s, when many haemophiliacs were infected by HIV or hepatitis C virus by receiving plazma FactorVIII concentrates. This resulted in a quick and powerful development of screening as well as pathogen-inactivating methods, which reduced pathogen contamination and transmission to minimal levels. Times and pathogens are continously and rather quickly changing, so during the last decade many - not only egzotic - new pathogens and diseases were recognised, and some of them (e.g., Zyka virus, Ebola, hepatitis E virus, etc.) can also be transmitted by blood or blood-component transfusions, and in some instances they escape from standard screening and inactivation procedures. Hereby we try to focus and draw attention to some of these potentially pathogenic new bloodborne microbiological agents, and along with this we try to emphasize the significance of application of updated next generation screening and inactivation procedures. Interestingly a recent British trial, based on large population data, showed some evidence of a slight increase of non-Hodgkin lymphoma incidence in patients with multiple previous transfusions. Probably these facts are even more important in haemophiliacs, who receive prophylactic treatment 3 times weekly either by plasma factor concentrates derived from multiple donors or by gene synthetic factor sources. It is important that haemophiliac patient and family should receive the necessary information, and go for a fully informed consent based on the potential advantages and hazards of a particular treatment modality, the same way as in the chronic treatment of other diseases.

KW - Inactivation

KW - Newly recognised bloodborne pathogens

KW - Plasm derived coagulation factor concentrates

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=85053002498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053002498&partnerID=8YFLogxK

U2 - 10.1556/650.2018.31183

DO - 10.1556/650.2018.31183

M3 - Article

C2 - 30196714

AN - SCOPUS:85053002498

VL - 159

SP - 1495

EP - 1500

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 37

ER -